Cargando…

Antileishmanial activity of MDL 28170, a potent calpain inhibitor

Several calpain inhibitors are under development and some are useful agents against important human pathogens. We therefore investigated the effect of MDL 28170, a potent calpain inhibitor, on the growth of Leishmania amazonensis. After 48 h of treatment, the inhibitor exhibited a dose-dependent ant...

Descripción completa

Detalles Bibliográficos
Autores principales: d’Avila-Levy, Claudia M., Marinho, Fernanda A., Santos, Lívia O., Martins, Juliana L., Santos, André L.S., Branquinha, Marta H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. and the International Society of Chemotherapy. 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126437/
https://www.ncbi.nlm.nih.gov/pubmed/16842979
http://dx.doi.org/10.1016/j.ijantimicag.2006.03.021
_version_ 1783516145836359680
author d’Avila-Levy, Claudia M.
Marinho, Fernanda A.
Santos, Lívia O.
Martins, Juliana L.
Santos, André L.S.
Branquinha, Marta H.
author_facet d’Avila-Levy, Claudia M.
Marinho, Fernanda A.
Santos, Lívia O.
Martins, Juliana L.
Santos, André L.S.
Branquinha, Marta H.
author_sort d’Avila-Levy, Claudia M.
collection PubMed
description Several calpain inhibitors are under development and some are useful agents against important human pathogens. We therefore investigated the effect of MDL 28170, a potent calpain inhibitor, on the growth of Leishmania amazonensis. After 48 h of treatment, the inhibitor exhibited a dose-dependent antileishmanial activity, with a 50% lethal dose (LD(50)) of 23.3 μM. The inhibitor promoted cellular alterations, such as the parasites becoming short and round. A calpain-like protein migrating at 80 kDa was identified by Western blotting. In addition, the calpain-like molecules were identified on the cell surface of the flagellate. These results add new in vitro insights into the exploitation of calpain inhibitors in treating parasitic infections and add this family of peptidases to the list of potential targets for development of more potent and specific inhibitors against trypanosomatids.
format Online
Article
Text
id pubmed-7126437
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Elsevier B.V. and the International Society of Chemotherapy.
record_format MEDLINE/PubMed
spelling pubmed-71264372020-04-08 Antileishmanial activity of MDL 28170, a potent calpain inhibitor d’Avila-Levy, Claudia M. Marinho, Fernanda A. Santos, Lívia O. Martins, Juliana L. Santos, André L.S. Branquinha, Marta H. Int J Antimicrob Agents Article Several calpain inhibitors are under development and some are useful agents against important human pathogens. We therefore investigated the effect of MDL 28170, a potent calpain inhibitor, on the growth of Leishmania amazonensis. After 48 h of treatment, the inhibitor exhibited a dose-dependent antileishmanial activity, with a 50% lethal dose (LD(50)) of 23.3 μM. The inhibitor promoted cellular alterations, such as the parasites becoming short and round. A calpain-like protein migrating at 80 kDa was identified by Western blotting. In addition, the calpain-like molecules were identified on the cell surface of the flagellate. These results add new in vitro insights into the exploitation of calpain inhibitors in treating parasitic infections and add this family of peptidases to the list of potential targets for development of more potent and specific inhibitors against trypanosomatids. Elsevier B.V. and the International Society of Chemotherapy. 2006-08 2006-07-13 /pmc/articles/PMC7126437/ /pubmed/16842979 http://dx.doi.org/10.1016/j.ijantimicag.2006.03.021 Text en Copyright © 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
d’Avila-Levy, Claudia M.
Marinho, Fernanda A.
Santos, Lívia O.
Martins, Juliana L.
Santos, André L.S.
Branquinha, Marta H.
Antileishmanial activity of MDL 28170, a potent calpain inhibitor
title Antileishmanial activity of MDL 28170, a potent calpain inhibitor
title_full Antileishmanial activity of MDL 28170, a potent calpain inhibitor
title_fullStr Antileishmanial activity of MDL 28170, a potent calpain inhibitor
title_full_unstemmed Antileishmanial activity of MDL 28170, a potent calpain inhibitor
title_short Antileishmanial activity of MDL 28170, a potent calpain inhibitor
title_sort antileishmanial activity of mdl 28170, a potent calpain inhibitor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126437/
https://www.ncbi.nlm.nih.gov/pubmed/16842979
http://dx.doi.org/10.1016/j.ijantimicag.2006.03.021
work_keys_str_mv AT davilalevyclaudiam antileishmanialactivityofmdl28170apotentcalpaininhibitor
AT marinhofernandaa antileishmanialactivityofmdl28170apotentcalpaininhibitor
AT santosliviao antileishmanialactivityofmdl28170apotentcalpaininhibitor
AT martinsjulianal antileishmanialactivityofmdl28170apotentcalpaininhibitor
AT santosandrels antileishmanialactivityofmdl28170apotentcalpaininhibitor
AT branquinhamartah antileishmanialactivityofmdl28170apotentcalpaininhibitor